Epicurus, 30 mg capsules 14 pcs

Epicur is an anti-ulcer agent. Specific proton pump inhibitor (H+K+ATPase); metabolized in the parietal cells of the stomach to active sulfonamide derivatives, which inactivate sulfhydryl groups of H+K+ATPase. Blocks the final stage of hydrochloric acid synthesis, reducing basal and stimulated secretion, regardless of the nature of the irritant.

The inhibition of hydrochloric acid production at a dose of 30 mg is 80-97%. Does not affect the motility of the gastrointestinal tract. The inhibitory effect increases during the first four days of administration. After discontinuation of the dose, acidity remains below 50% of the basal level for 39 hours, “ricochet” increase in secretion is not observed. Secretory activity is restored 3-4 days after discontinuation of the drug. In patients with Zollinger-Ellison syndrome the action is longer.

Pharmacokinetics

Absorption – high, bioavailability – 80% (eating reduces absorption and bioavailability by 50%, but inhibitory effect on gastric secretion remains the same, regardless of meals).

The time of onset of maximum concentration (C max) after oral administration of 30 mg is 1.5-2.2 h, Cmax- 0.75-1.15 mg/l. Binding with plasma proteins is 97.7-99.4%. It is actively metabolized by the “primary passage” through the liver.

The elimination half-life is 1.3-1.7 hours. Excretion by the kidneys (as metabolites) – 14-23% and through the intestine. With hepatic insufficiency and in elderly patients excretion slows down.

Indications

Peptic ulcer of the stomach and duodenum.
Reflux esophagitis, erosive ulcerative esophagitis
Erosive and ulcerative lesions of the stomach and duodenum associated with the use of non-steroidal anti-inflammatory drugs, stress ulcers.
Erosive and ulcerative lesions of the stomach and duodenum associated with Helicobacter pylori (as part of complex therapy).
Zollinger-Ellison syndrome

Pharmacological effect

Epicurus is an antiulcer agent. Specific inhibitor of the proton pump (H+K+ATPase); metabolized in the parietal cells of the stomach to active sulfonamide derivatives, which are inactivated by the sulfhydryl groups of H+K+ATPase. Blocks the final stage of hydrochloric acid synthesis, reducing basal and stimulated secretion, regardless of the nature of the stimulus.

Inhibition of hydrochloric acid production at a dose of 30 mg is 80-97%. Does not affect gastrointestinal motility. The inhibitory effect increases in the first four days of administration. After stopping the intake, acidity remains below 50% of the basal level for 39 hours, and there is no “rebound” increase in secretion. Secretory activity is restored 3-4 days after stopping the drug. In patients with Zollinger-Ellison syndrome, the effect lasts longer.

Pharmacokinetics

Absorption is high, bioavailability is 80% (food intake reduces absorption and bioavailability by 50%, but the inhibitory effect on gastric secretion remains the same, regardless of food intake).

The time of onset of maximum concentration (Cmax) after oral administration of 30 mg is 1.5-2.2 hours, Cmax is 0.75-1.15 mg/l. Bonding with plasma proteins is 97.7-99.4%. Actively metabolized during the “primary passage” through the liver.

The half-life is 1.3-1.7 hours. Excretion by the kidneys (in the form of metabolites) – 14-23% and through the intestines. In liver failure and in elderly patients, excretion slows down.

Special instructions

Before starting treatment, it is necessary to exclude the presence of a malignant process in the upper gastrointestinal tract, because taking the drug can “mask” symptoms and complicate diagnosis.

Active ingredient

Lansoprazole

Composition

1 capsule contains:

Active ingredients:

lansoprazole pellets – 353 mg, containing lansoprazole – 30 mg,

Excipients:

sugar pellets (sucrose),

sugar syrup (sucrose),

mannitol,

calcium carboxymethylcellulose (calcium carmellose),

magnesium carbonate,

sodium phosphate disubstituted (sodium hydrogen phosphate),

sodium lauryl sulfate,

polyvinylpyrrolidone K-30 (povidone),

Tween 80 (polysorbate 80),

Hydroxypropyl methylcellulose (hypromellose),

acrylic coating L30DA (methacrylic acid),

talc,

polyethylene glycol 6000 (macrogol),

titanium dioxide,

sodium hydroxide.

Hard gelatin capsules (quinoline yellow [E 104], patent blue V, gelatin) methyl parahydroxybenzoate, propyl parahydroxybenzoate)

Pregnancy

Contraindicated in the first trimester. In the second and third trimester it is possible if the expected benefit of therapy outweighs the potential risk to the fetus. Breastfeeding should be stopped during treatment.

Contraindications

Hypersensitivity to the components of the drug Epicur,
malignant neoplasms of the gastrointestinal tract,
pregnancy (first trimester),
lactation period,
age up to 12 years (safety and effectiveness in patients under 12 years of age have not been sufficiently studied).

With caution: Hepatic and/or renal failure. Old age.

Side Effects

From the digestive system: increased or decreased appetite, nausea, abdominal pain, rarely – diarrhea or constipation; in some cases – ulcerative colitis, candidiasis of the gastrointestinal tract, increased activity of “liver” enzymes, increased levels of bilirubin in the blood.

From the nervous system: headache; rarely – malaise, dizziness, drowsiness, depression, anxiety.

From the respiratory system: rarely – cough, pharyngitis, rhinitis, upper respiratory tract infection, influenza-like syndrome.

From the hematopoietic organs: rarely – thrombocytopenia (with hemorrhagic manifestations); in some cases – anemia.

Allergic reactions: skin rash; in some cases – photosensitivity, erythema multiforme.

Other: rarely – myalgia, alopecia.

Interaction

Slows down the elimination of drugs metabolized in the liver by microsomal oxidation (including diazepam, phenytoin, indirect anticoagulants). Reduces the clearance of theophylline by 10%.

Changes the pH-dependent absorption of drugs belonging to the groups of weak acids (deceleration) and bases (acceleration).

Sucralfate reduces the bioavailability of lansoprazole by 30% (it is necessary to observe an interval of 30-40 minutes between taking these drugs)

Antacids slow down and reduce the absorption of lansoprazole (they should be prescribed 1 hour before or 1-2 hours after taking lansoprazole).

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 °C

Shelf life

2 years

Manufacturer

Obolenskoye FP JSC, Russia